Causaly vs PubMed®: 2x as many relevant articles identified by Causaly using the same data
by Anna Tzani
Medical Affairs, Regulatory and Pharmacovigilance experts are interested in identifying all the available evidence related to a drug’s safety profile. In order to accurately conduct a drug safety assessment, the relevance of results is pivotal, given the vast amount of data sources and time limitations.
A case study was conducted to compare Causaly and PubMed as resources for investigating the effects of Natalizumab on Psoriasis. The analysis compares the two platforms with respect to the number and relevance of articles retrieved.
Causaly identifies 2x as many articles, including all the PubMed articles, and more relevant results.
Effects of Natalizumab on Psoriasis: Causaly vs PubMed®
Apart from the evidence points relating Natalizumab and Psoriasis directly, indirect associations, that may be of interest, were also identified. For example, we discovered that Natalizumab increases IL17A secretion, an interleukin with a well known pathogenic role in Psoriasis (Figure 3) (5).
Drug safety assessments are ongoing processes that require a lot of investigation time and effort.
Causaly AI finds more relevant articles than PubMed alone, using its advanced machine-reading technology.
Therefore, using Causaly’s AI technology, Medical Affairs departments, Pharmacovigilance officers and Regulatory experts can keep up-to-date with recent publications and perform a holistic and accurate evaluation of drug safety profiles.